Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.74 [0.64, 0.86] | | < 1 | | 59% | 5 studies (5/-) | 100.0 % | low | serious | high | crucial | - |
deaths (OS) (extension) | 0.81 [0.73, 0.91] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | low | not evaluable | high | important | - |
progression or deaths (PFS) | 0.83 [0.70, 0.98] | | < 1 | | 72% | 4 studies (4/-) | 98.8 % | low | not evaluable | high | important | - |
objective responses (ORR) | 2.57 [1.79, 3.69] | | > 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
AE (any grade) | 0.99 [0.55, 1.78] | | < 1 | | 48% | 4 studies (4/-) | 51.7 % | low | not evaluable | high | non important | - |
AE (grade 3-4) | 1.31 [0.85, 2.03] | | < 1 | | 86% | 4 studies (4/-) | 11.0 % | low | not evaluable | high | non important | - |
AE leading to death (grade 5) | 1.05 [0.69, 1.61] | | < 1 | | 0% | 4 studies (4/-) | 40.8 % | low | not evaluable | high | non important | - |
AE leading to treatment discontinuation (any grade) | 1.50 [0.89, 2.53] | | < 1 | | 77% | 4 studies (4/-) | 6.4 % | low | not evaluable | high | non important | - |
SAE (any grade) | 1.38 [0.92, 2.07] | | < 1 | | 0% | 1 study (1/-) | 6.1 % | NA | not evaluable | | non important | - |
STRAE (grade 3-4) | 0.30 [0.22, 0.41] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE leading to discontinuation (any grade) | 0.53 [0.28, 1.00] | | < 1 | | 0% | 1 study (1/-) | 97.5 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
AE (grade 3-4) endpoints 00 |
Abdominal pain AE (grade 3-4) | 0.47 [0.12, 1.90] | | < 1 | | 0% | 1 study (1/-) | 85.6 % | NA | not evaluable | | non important | - |
Acute kidney injury AE (grade 3-4) | 0.16 [0.02, 1.51] | | < 1 | | 0% | 1 study (1/-) | 94.5 % | NA | not evaluable | | non important | - |
Alopecia AE (grade 3-4) | 0.47 [0.01, 23.97] | | < 1 | | 0% | 1 study (1/-) | 64.3 % | NA | not evaluable | | non important | - |
Anaemia AE (grade 3-4) | 1.07 [0.32, 3.53] | | < 1 | | 0% | 1 study (1/-) | 45.7 % | NA | not evaluable | | non important | - |
Asthenia AE (grade 3-4) | 0.12 [0.01, 1.05] | | < 1 | | 0% | 1 study (1/-) | 97.2 % | NA | not evaluable | | non important | - |
Constipation AE (grade 3-4) | 0.47 [0.01, 23.97] | | < 1 | | 0% | 1 study (1/-) | 64.3 % | NA | not evaluable | | non important | - |
Cough AE (grade 3-4) | 0.24 [0.01, 7.07] | | < 1 | | 0% | 1 study (1/-) | 79.4 % | NA | not evaluable | | non important | - |
Decreased appetite AE (grade 3-4) | 0.31 [0.09, 1.11] | | < 1 | | 0% | 1 study (1/-) | 96.4 % | NA | not evaluable | | non important | - |
Diarrhoea AE (grade 3-4) | 0.34 [0.12, 1.01] | | < 1 | | 0% | 1 study (1/-) | 97.4 % | NA | not evaluable | | non important | - |
Dyspepsia AE (grade 3-4) | 0.12 [0.01, 2.61] | | < 1 | | 0% | 1 study (1/-) | 90.9 % | NA | not evaluable | | non important | - |
Dyspnoea AE (grade 3-4) | 0.63 [0.14, 2.84] | | < 1 | | 0% | 1 study (1/-) | 72.7 % | NA | not evaluable | | non important | - |
Epistaxis AE (grade 3-4) | 0.24 [0.01, 7.07] | | < 1 | | 0% | 1 study (1/-) | 79.4 % | NA | not evaluable | | non important | - |
Fatigue AE (grade 3-4) | 0.75 [0.24, 2.34] | | < 1 | | 0% | 1 study (1/-) | 68.8 % | NA | not evaluable | | non important | - |
Hypertension AE (grade 3-4) | 1.29 [0.73, 2.28] | | < 1 | | 0% | 1 study (1/-) | 18.8 % | NA | not evaluable | | non important | - |
Increase AST AE (grade 3-4) | 1.39 [0.61, 3.18] | | < 1 | | 0% | 1 study (1/-) | 21.8 % | NA | not evaluable | | non important | - |
Increased ALT AE (grade 3-4) | 2.91 [0.64, 13.19] | | < 1 | | 0% | 1 study (1/-) | 8.3 % | NA | not evaluable | | non important | - |
Infusion-related reaction AE (grade 3-4) | 7.75 [0.44, 135.83] | | < 1 | | 0% | 1 study (1/-) | 8.3 % | NA | not evaluable | | non important | - |
Nausea AE (grade 3-4) | 0.47 [0.03, 7.61] | | < 1 | | 0% | 1 study (1/-) | 70.0 % | NA | not evaluable | | non important | - |
Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4) | 0.02 [0.00, 0.28] | | < 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | non important | - |
Proteinuria AE (grade 3-4) | 4.86 [0.62, 38.30] | | < 1 | | 0% | 1 study (1/-) | 6.8 % | NA | not evaluable | | non important | - |
Pruritus AE (grade 3-4) | 0.47 [0.01, 23.97] | | < 1 | | 0% | 1 study (1/-) | 64.3 % | NA | not evaluable | | non important | - |
Pyrexia AE (grade 3-4) | 0.95 [0.17, 5.23] | | < 1 | | 0% | 1 study (1/-) | 52.4 % | NA | not evaluable | | non important | - |
Rash AE (grade 3-4) | 0.06 [0.00, 1.10] | | < 1 | | 0% | 1 study (1/-) | 97.0 % | NA | not evaluable | | non important | - |
Thrombocytopenia AE (grade 3-4) | 0.95 [0.23, 3.84] | | < 1 | | 0% | 1 study (1/-) | 53.0 % | NA | not evaluable | | non important | - |
Vomiting AE (grade 3-4) | 0.95 [0.09, 10.54] | | < 1 | | 0% | 1 study (1/-) | 51.7 % | NA | not evaluable | | non important | - |
Weight decreased AE (grade 3-4) | 0.24 [0.01, 7.07] | | < 1 | | 0% | 1 study (1/-) | 79.4 % | NA | not evaluable | | non important | - |